(21585118), M. M. M., (21585121), A. C. M., (18491067), B. J. C., (18491064), J. M. S., (18491052), B. A. M., (18491061), P. J. D., . . . (18491049), P. C. (2025). Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2.
Lua i Stíl Chicago (17ú heag.)(21585118), Monica M. Mita, et al. Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2. 2025.
Lua MLA (9ú heag.)(21585118), Monica M. Mita, et al. Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2. 2025.